Published online before print December 2, 2004, doi: 10.1161/01.RES.0000152262.22968.72
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Cellular Biology |
cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism
From the Division of Cardiology (E.T., H.C.C., D.B., J.M., T.I., D.A.K.), Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Md; Dulbecco Telethon Institute at the Venetian Institute of Molecular Medicine (M.M., M.Z.), Padova, Italy; Department of Pharmacology and Toxicology (E.M.), Ruhr-Universität Bochum, Medizinische Fakultät, Bochum, Germany; Department of Pharmacology (D.C.M., K.A., C.J.S.), New York Medical College, Valhalla; and Department of Pharmacology (W.R.D.), University of Vermont, Burlington.
Correspondence to David A. Kass, Ross Research Bldg 835, Johns Hopkins University Hospital, 720 Rutland Ave, Baltimore, MD 21205. E-mail dkass{at}jhmi.edu
ß-Adrenergic agonists stimulate cardiac contractility and simultaneously blunt this response by coactivating NO synthase (NOS3) to enhance cGMP synthesis and activate protein kinase G (PKG-1). cGMP is also catabolically regulated by phosphodiesterase 5A (PDE5A). PDE5A inhibition by sildenafil (Viagra) increases cGMP and is used widely to treat erectile dysfunction; however, its role in the heart and its interaction with ß-adrenergic and NOS3/cGMP stimulation is largely unknown. In nontransgenic (control) murine in vivo hearts and isolated myocytes, PDE5A inhibition (sildenafil) minimally altered rest function. However, when the hearts or isolated myocytes were stimulated with isoproterenol, PDE5A inhibition was associated with a suppression of contractility that was coupled to elevated cGMP and increased PKG-1 activity. In contrast, NOS3-null hearts or controls with NOS inhibited by NG-nitro-L-arginine methyl ester, or soluble guanylate cyclase (sGC) inhibited by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one, showed no effect of PDE5A inhibition on ß-stimulated contractility or PKG-1 activation. This lack of response was not attributable to altered PDE5A gene or protein expression or in vitro PDE5A activity, but rather to an absence of sGC-generated cGMP specifically targeted to PDE5A catabolism and to a loss of PDE5A localization to z-bands. Re-expression of active NOS3 in NOS3-null hearts by adenoviral gene transfer restored PDE5A z-band localization and the antiadrenergic efficacy of PDE5A inhibition. These data support a novel regulatory role of PDE5A in hearts under adrenergic stimulation and highlight specific coupling of PDE5A catabolic regulation with NOS3-derived cGMP attributable to protein subcellular localization and targeted synthetic/catabolic coupling.
Key Words: PDE5 • phosphodiesterase • sildenafil • nitric oxide synthase • contractility • z-band
This article has been cited by other articles:
 |
|
 |
|
  T. Nagayama, M. Zhang, S. Hsu, E. Takimoto, and D. A. Kass Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 380 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Tankersley, H. C. Champion, E. Takimoto, K. Gabrielson, D. Bedja, V. Misra, H. El-Haddad, R. Rabold, and W. Mitzner Exposure to inhaled particulate matter impairs cardiac function in senescent mice Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R252 - R263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. M. Nausch, J. Ledoux, A. D. Bonev, M. T. Nelson, and W. R. Dostmann Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors PNAS, January 8, 2008; 105(1): 365 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, H. C. Champion, and J. A. Beavo Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation Circ. Res., November 26, 2007; 101(11): 1084 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass Hypertrophied Right Hearts Get Two for the Price of One: Can Inhibiting Phosphodiesterase Type 5 Also Inhibit Phosphodiesterase Type 3? Circulation, July 17, 2007; 116(3): 233 - 235. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion Phosphodiesterase regulation of nitric oxide signaling Cardiovasc Res, July 15, 2007; 75(2): 303 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Perez, M. R. Piaggio, I. L. Ennis, C. D. Garciarena, C. Morales, E. M. Escudero, O. H. Cingolani, G. Chiappe de Cingolani, X.-P. Yang, and H. E. Cingolani Phosphodiesterase 5A Inhibition Induces Na+/H+ Exchanger Blockade and Protection Against Myocardial Infarction Hypertension, May 1, 2007; 49(5): 1095 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Takimoto, D. Belardi, C. G. Tocchetti, S. Vahebi, G. Cormaci, E. A. Ketner, A. L. Moens, H. C. Champion, and D. A. Kass Compartmentalization of Cardiac {beta}-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 Circulation, April 24, 2007; 115(16): 2159 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Hsu, H. C. Champion, S. A. Campbell-Lee, T. J. Bivalacqua, E. A. Manci, B. A. Diwan, D. M. Schimel, A. E. Cochard, X. Wang, A. N. Schechter, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability Blood, April 1, 2007; 109(7): 3088 - 3098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Elrod, J. J. M. Greer, and D. J. Lefer Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H342 - H347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Maslov, V. P. Chacko, M. Stuber, A. L. Moens, D. A. Kass, H. C. Champion, and R. G. Weiss Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H387 - H391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fesler, A. Pagnamenta, B. Rondelet, F. Kerbaul, and R. Naeije Effects of sildenafil on hypoxic pulmonary vascular function in dogs J Appl Physiol, October 1, 2006; 101(4): 1085 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R.V. Castro, I. Verde, D. M.F. Cooper, and R. Fischmeister Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes Circulation, May 9, 2006; 113(18): 2221 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mongillo, C. G. Tocchetti, A. Terrin, V. Lissandron, Y.-F. Cheung, W. R. Dostmann, T. Pozzan, D. A. Kass, N. Paolocci, M. D. Houslay, et al. Compartmentalized Phosphodiesterase-2 Activity Blunts {beta}-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway Circ. Res., February 3, 2006; 98(2): 226 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Borlaug, V. Melenovsky, T. Marhin, P. Fitzgerald, and D. A. Kass Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans Circulation, October 25, 2005; 112(17): 2642 - 2649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass Ventricular Arterial Stiffening: Integrating the Pathophysiology Hypertension, July 1, 2005; 46(1): 185 - 193. [Abstract] [Full Text] [PDF]
|
|